MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...
MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...
NSAIDs should be considered as first-line treatment for children with acute pain, with ketamine and mid- to high-potency opioids as other effective options.
Zacks Small Cap Research on MSN16h
MIRA Makes Another Pain Management StrideMIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback